Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis

详细信息    查看全文

• 作者：Z. Birsin Özçakar ; Semanur Özdel ; Songül Yılmaz…
• 关键词：Amyloidosis ; Anakinra ; Canakinumab ; Familial Mediterranean fever ; Treatment
• 刊名：Clinical Rheumatology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：35
• 期：2
• 页码：441-446
• 全文大小：129 KB
• 参考文献：1.Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65:318–324PubMed
  2.Mamou H, Cattan R (1952) La maladie periodique (sur 14 cas personnels dont 8 compliques de nephropathies). Sem Hop Paris 28:1062–1070PubMed
  3.Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302PubMed
  4.Özkan E, Okur Ö, Ekmekçi A, Özcan R, Tağ T (1972) A new approach to the treatment of periodic fever. Med Bull İstanbul 5:44–49
  5.Touitou I, Sarkisian T, Medlej-Hashim M et al (2007) Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56:1706–1712CrossRef PubMed
  6.Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and review of the literature. Semin Arthritis Rheum 41:265–271CrossRef PubMed
  7.Akgul S, Kılıç E, Kılıç G, Özgöçmen S (2013) Efficacy and safety of biological treatments in familial Mediterranean fever. Am J Med Sci 346:137–141CrossRef PubMed
  8.Ozçakar ZB, Yüksel S, Ekim M, Yalçınkaya F (2012) Infliximab therapy for familial mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol 31:1267–1271CrossRef PubMed
  9.Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P (2014) Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95:89–97CrossRef PubMed
  10.Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T (2007) Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 146:825–826CrossRef PubMed
  11.Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicine resistant patient. Neth J Med 66:489–491PubMed
  12.Stojanovic KS, Delmas Y, Torres PU et al (2012) Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 27:1898–1901CrossRef
  13.Moser C, Pohl G, Haslinger I et al (2009) Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24:676–678CrossRef PubMed
  14.Alpay N, Şumnu A, Çalışkan Y, Yazıcı H, Türkmen A, Gül A (2012) Efficacy of anakinra treatment in a patient with colchicine resistant familial Mediterranean fever. Rheumatol Int 32:3277–3279CrossRef PubMed
  15.Yalçınkaya F, Özen S, Özçakar ZB et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398CrossRef
  16.Aksentijevich I, Torosyan Y, Samuels J et al (1999) Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the ashkenazi jewish population. Am J Hum Genet 64:949–962PubMedCentral CrossRef PubMed
  17.Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the turkish population. Eur J Hum Genet 9:553–555CrossRef PubMed
  18.The International FMF Consortium (1997) Ancient missense mutations in a new member of the roret gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRef
  19.The French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25–31CrossRef
  20.Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146:467–478PubMedCentral CrossRef PubMed
  21.Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64–69CrossRef PubMed
  22.Özdoğan H, Arısoy N, Kasapçopur Ö et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327PubMed
  23.Tekin M, Yalçınkaya F, Tümer N et al (1999) Familial Mediterranean fever—renal involvement by diseases other than amyloid. Nephrol Dial Transplant 14:475–479CrossRef PubMed
  24.Livneh A, Langevitz P, Zemer D et al (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26:612–627CrossRef PubMed
  25.Ben-Chetrit E, Levy M (1991) Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 20:241–246CrossRef PubMed
  26.Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977CrossRef PubMed
  27.Lidar M, Yonath H, Shechter N et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12:72–76CrossRef PubMed
  28.Ozcakar ZB, Elhan AH, Yalcinkaya F (2014) Can colchicine response be predicted in familial Mediterranean fever patients. Rheumatology (Oxford). doi:10.​1093/​rheumatology/​keu138
  29.Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29:87–90
  30.Dinarello CA, van der Meer JWM (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 25:469–484PubMedCentral CrossRef PubMed
  
• 作者单位：Z. Birsin Özçakar (1)
  Semanur Özdel (2)
  Songül Yılmaz (3)
  E. Didem Kurt-Şükür (3)
  Mesiha Ekim (1)
  Fatoş Yalçınkaya (4)
  
  1. Department of Pediatrics, Division of Pediatric Rheumatology & Nephrology, Ankara University School of Medicine, 06100, Ankara, Turkey
  2. Department of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, Turkey
  3. Department of Pediatrics, Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
  4. Department of Pediatrics, Division of Pediatric Rheumatology & Nephrology, Ankara University School of Medicine, Çınar Sitesi 5.Blok No:62, 06530, Ümitköy, Turkey
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  
• 出版者：Springer London
• ISSN：1434-9949

文摘

Colchicine is the standard treatment in familial Mediterranean fever (FMF) patients. New treatment strategies are needed in FMF patients who were unresponsive to colchicine therapy or who had developed amyloidosis. The aim of this study was to present clinical-laboratory features and treatment responses of pediatric FMF patients that were treated with anti-IL-1 therapies. Files of patients who had been followed in our department with diagnosis of FMF were retrospectively evaluated. Patients that have been receiving anti-IL-1 therapies (anakinra or canakinumab) were included to the study. All patients were interpreted with respect to the demographic data, clinical and laboratory features of the disease, genetic analysis of MEFV mutations and treatment responses. Among 330 currently registered FMF patients, 13 patients were included to the study. Seven of them received anti-IL-1 therapy due to colchicine resistance and 6 due to FMF-related amyloidosis (1 of them with nephrotic syndrome, 2 with chronic kidney disease, 3 with renal transplantation). In all treated patients, attacks completely disappeared or decreased in frequency; partial remission occured in nephrotic syndrome patient; and their life quality improved. Anti-IL-1 therapies can be successfully used in colchicine-resistant FMF patients and patients with amyloidosis during childhood and adolescent period without major side effects. Keywords Amyloidosis Anakinra Canakinumab Familial Mediterranean fever Treatment